A nurse is caring for a client who has cirrhosis of the liver and is receiving spironolactone. Which of the following findings indicates that the client is responding to the treatment?

A) Hematuria: Hematuria, or blood in the urine, is not typically associated with an allergic reaction to cefaclor. Allergic reactions usually manifest with symptoms such as rash, itching, swelling, or difficulty breathing. Hematuria is more likely indicative of a urinary tract infection, kidney stones, or another non-allergic issue.

B) Pruritus: Pruritus, or itching, is a common symptom of an allergic reaction to medications like cefaclor. Itching can occur on the skin or mucous membranes and may be accompanied by other allergic symptoms such as rash, hives, or swelling. Therefore, the presence of pruritus should raise suspicion for a potential allergic reaction to cefaclor.

C) Slurred speech: Slurred speech is not a typical manifestation of an allergic reaction to cefaclor. It is more commonly associated with neurological conditions, intoxication, stroke, or side effects of certain medications, rather than an allergic response to antibiotics.

D) Tremor: Tremor, or involuntary shaking, is not a characteristic sign of an allergic reaction to cefaclor. Tremors can have various causes, including neurological disorders, medication side effects, or metabolic abnormalities. While tremors can occur in severe allergic reactions (anaphylaxis), they are not among the primary symptoms.

A) WBC count: Filgrastim is a granulocyte colony-stimulating factor (G-CSF) medication used to stimulate the production of white blood cells (WBCs), particularly neutrophils, in individuals with neutropenia. Therefore, monitoring the WBC count is essential to evaluate the effectiveness of filgrastim therapy. An increase in WBC count indicates a response to treatment, helping to prevent or manage neutropenic complications such as infections.

B) INR: The international normalized ratio (INR) is a laboratory test used to monitor the effectiveness of anticoagulant therapy, particularly warfarin (Coumadin). It measures the clotting ability of the blood and is not directly related to filgrastim therapy. Therefore, monitoring the INR is not appropriate for evaluating the effectiveness of filgrastim treatment.

C) BUN: Blood urea nitrogen (BUN) is a laboratory test used to assess kidney function and hydration status. It measures the concentration of urea nitrogen in the blood and is not directly related to filgrastim therapy. Monitoring BUN levels may be indicated for assessing renal function in certain clinical contexts but is not specific to evaluating the effectiveness of filgrastim treatment.

D) Potassium level: Monitoring potassium levels is important for assessing electrolyte balance and kidney function but is not directly related to filgrastim therapy. Potassium levels may be affected by various factors, including medications, diet, and renal function. However, they do not directly reflect the effectiveness of filgrastim in stimulating WBC production.